Stonepine Capital Management’s Boston Scientific BSX Stock Holding History

Stonepine Capital Management’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.4M	Buy	+55,000	New	+$2.55M	1.51%	20

Other funds holding BSX

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $296B AUM 23.14% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return

Stonepine Capital Management's BSX Position: Q3 2026 in Review

Stonepine Capital Management opened a new position in Boston Scientific (BSX) in Q3 2026: 55,000 shares worth $2.4M. The stake represents 1.51% of the portfolio and ranks #20 among its holdings.

1,274 funds tracked by Wall St. Rank hold BSX as of Q3 2026.

Stonepine Capital Management held 55,000 shares of Boston Scientific worth $2.4M as of Q3 2026.
Boston Scientific was a new Stonepine Capital Management position in Q3 2026.
Boston Scientific made up 1.51% of Stonepine Capital Management's portfolio in Q3 2026, its #20 holding.
1,274 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2026.

Based on Stonepine Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.